Natural bovine osteogenin and recombinant human bone morphogenetic protein-2B are equipotent in the maintenance of proteoglycans in bovine articular cartilage explant cultures

• Published in: The Journal of biological chemistry Vol. 267; no. 6; pp. 3691 - 3695
• Main Authors: LUYTEN, F. P, YU, Y. M, YANAGISHITA, M, VUKICEVIC, S, GLENN HAMMONDS, R, REDDI, A. H
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Biochemistry and Molecular Biology 25.02.1992
• Subjects: Aging - metabolism; Animals; Biological and medical sciences; Bone Morphogenetic Protein 3; Bone Morphogenetic Proteins; Cartilage, Articular - drug effects; Cartilage, Articular - metabolism; Cattle; Cell physiology; Culture Techniques; Fundamental and applied biological sciences. Psychology; Glycosaminoglycans - metabolism; Growth Substances - metabolism; Humans; Insulin-Like Growth Factor I - pharmacology; Molecular and cellular biology; Proteins - metabolism; Proteoglycans - metabolism; Recombinant Proteins - metabolism; Responses to growth factors, tumor promotors, other factors; Transforming Growth Factor beta - pharmacology; Proteoglycan; Vertebrata; Mammalia; Bone morphogenetic protein; Articular cartilage; Radiolabelling; Transforming growth factor; Tissue culture
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/S0021-9258(19)50580-4

Osteogenin and related bone morphogenetic proteins are members of the transforming growth factor-beta superfamily, and were isolated by their ability to induce cartilage and bone formation in vivo. The influence of osteogenin, purified from bovine bone, and of recombinant human bone morphogenetic protein-2B (BMP-2B) has been examined in bovine articular cartilage explants. Both differentiation factors stimulated in a dose-dependent manner the synthesis of proteoglycans and decreased their rate of degradation. At a dose of 30 ng/ml, proteoglycan synthesis was increased to levels observed with either 20 ng/ml insulin-like growth factor I, 10 ng/ml transforming growth factor-beta, or 20% fetal bovine serum. This increase of biosynthetic rates above basal medium levels was observed in young, adolescent, and adult tissues. Analysis of the size of the newly synthesized proteoglycans, the glycosaminoglycan chain size, and the glycosaminoglycan type of explants treated with osteogenin or BMP-2B were very comparable to each other, and to proteoglycans isolated from cartilage treated with either insulin-like growth factor I or fetal bovine serum. These results demonstrate that osteogenin and BMP-2B alone are capable of stimulating and maintaining the chondrocyte phenotype in vitro.